Trimetrexate isethionate is used for the treatment and research of Pneumocystis carinii pneumonia (PCP) and various cancers; it acts as an antibiotic and a potent, orally active dihydrofolate reductase (DHFR) inhibitor, inhibiting the growth of multiple cancer cell lines and leading to cell death by reducing the production of DNA and RNA precursors.